Dataset Information


Pandemic influenza vaccine: characterization of A/California/07/2009 (H1N1) recombinant hemagglutinin protein and insights into H1N1 antigen stability.

ABSTRACT: BACKGROUND: The recent H1N1 influenza pandemic illustrated the shortcomings of the vaccine manufacturing process. The A/California/07/2009 H1N1 pandemic influenza vaccine or A(H1N1)pdm09 was available late and in short supply as a result of delays in production caused by low yields and poor antigen stability. Recombinant technology offers the opportunity to shorten manufacturing time. A trivalent recombinant hemagglutinin (rHA) vaccine candidate for seasonal influenza produced using the baculovirus expression vector system (BEVS) was shown to be as effective and safe as egg-derived trivalent inactivated vaccine (TIV) in human clinical studies. In this study, we describe the characterization of the A/California/07/2009 rHA protein and compare the H1N1 pandemic rHA to other seasonal rHA proteins. RESULTS: Our data show that, like other rHA proteins, purified A/California/07/2009 rHA forms multimeric rosette-like particles of 20-40?nm that are biologically active and immunogenic in mice as assayed by hemagglutination inhibition (HAI) antibody titers. However, proteolytic digest analysis revealed that A/California/07/2009 rHA is more susceptible to proteolytic degradation than rHA proteins derived from other seasonal influenza viruses. We identified a specific proteolytic site conserved across multiple hemagglutinin (HA) proteins that is likely more accessible in A/California/07/2009 HA, possibly as a result of differences in its protein structure, and may contribute to lower antigen stability. CONCLUSION: We conclude that, similar to the recombinant seasonal influenza vaccine, recombinant A(H1N1)pdm09 vaccine is likely to perform comparably to licensed A(H1N1)pdm09 vaccines and could offer manufacturing advantages.

SUBMITTER: Feshchenko E 

PROVIDER: S-EPMC3538074 | BioStudies | 2012-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7012450 | BioStudies
2017-01-01 | S-EPMC5441160 | BioStudies
2019-01-01 | S-EPMC6331099 | BioStudies
2020-01-01 | S-EPMC7712556 | BioStudies
| S-EPMC5858567 | BioStudies
2021-01-01 | S-EPMC7767944 | BioStudies
1000-01-01 | S-EPMC3532823 | BioStudies
2017-01-01 | S-EPMC5414992 | BioStudies
2014-01-01 | S-EPMC4111912 | BioStudies
2013-01-01 | S-EPMC3834170 | BioStudies